The large randomized study by Crook et al. demonstrated that intermittent administration of androgen deprivation therapy should be considered the standard of care when patients with moderate and well-differentiated localized prostate cancer are treated for rising PSA levels after definitive radiotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zietman, A. L. et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95–09. J. Clin. Oncol. 28, 1106–1111 (2010).
Peters, M. et al. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World J. Urol. doi:10.1007/s00345-012-0928-8.
Crook, J. M. et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 367, 895–903 (2012).
Akakura, K. et al. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71, 2782–2790 (1993).
Shipley, W. U. et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86–10. Int. J. Radiat. Oncol. Biol. Phys. 64, 1162–1167 (2006).
Calais da Silva, F. E. et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur. Urol. 55, 1269–1277 (2009).
de Leval, J. et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin. Prostate Cancer. 1, 163–171 (2002).
Hussain, M. et al. Intermittent (IAD) versus continuos androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial [abstract]. J. Clin. Oncol. 30 (Suppl.), a4 (2012).
Miller, K. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J. Clin. Oncol. 25 (Suppl.), 5015 (2007).
Salonen, A. J. et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J. Urol. 187, 2074–2081 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W. U. Shipley declares he is a stock holder for Pfizer. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Mitin, T., Efstathiou, J. & Shipley, W. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol 9, 672–673 (2012). https://doi.org/10.1038/nrclinonc.2012.201
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.201
This article is cited by
-
A Time Scales Approach for Modeling Intermittent Hormone Therapy for Prostate Cancer
Bulletin of Mathematical Biology (2020)
